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Abstract: As the utility of magnetic resonance imaging (MRI) broadens, the importance of 
having specific and efficient contrast agents increases and in recent time there has been a huge 
development in the fields of molecular imaging and intracellular markers. Previous studies have 
shown that gadolinium oxide (Gd2O3) nanoparticles generate higher relaxivity than currently 
available Gd chelates: In addition, the Gd2O3 nanoparticles have promising properties for MRI 
cell tracking. The aim of the present work was to study cell labeling with Gd2O3 nanoparticles in 
hematopoietic cells and to improve techniques for monitoring hematopoietic stem cell migration 
by MRI. Particle uptake was studied in two cell lines: the hematopoietic progenitor cell line 
Ba/F3 and the monocytic cell line THP-1. Cells were incubated with Gd2O3 nanoparticles and it 
was investigated whether the transfection agent protamine sulfate increased the particle uptake. 
Treated cells were examined by electron microscopy and MRI, and analyzed for particle content 
by inductively coupled plasma sector field mass spectrometry. Results showed that particles were 
intracellular, however, sparsely in Ba/F3. The relaxation times were shortened with increasing 
particle concentration. Relaxivities, r1 and r2 at 1.5 T and 21°C, for Gd2O3 nanoparticles in dif-
ferent cell samples were 3.6–5.3 s−1 mM−1 and 9.6–17.2 s−1 mM−1, respectively. Protamine sulfate 
treatment increased the uptake in both Ba/F3 cells and THP-1 cells. However, the increased 
uptake did not increase the relaxation rate for THP-1 as for Ba/F3, probably due to aggregation 
and/or saturation effects. Viability of treated cells was not significantly decreased and thus, it 
was concluded that the use of Gd2O3 nanoparticles is suitable for this type of cell labeling by 
means of detecting and monitoring hematopoietic cells. In conclusion, Gd2O3 nanoparticles are 
a promising material to achieve positive intracellular MRI contrast; however, further particle 
development needs to be performed.
Keywords: gadolinium oxide, magnetic resonance imaging, contrast agent, cell labeling, 
Ba/F3 cells, THP-1 cells
Introduction
Magnetic resonance imaging (MRI) is an important technique for medical image 
diagnostics. It has a unique ability to distinguish soft body tissue through endogenous 
contrast mechanisms. Exogenous contrast agents are frequently used in MRI for con-
trast enhancement and there are a variety of agents commercially available. Negative 
contrast is obtained by using superparamagnetic iron oxide particles. However, the 
most common clinically used substances, which give positive contrast enhancement, 
are paramagnetic chelates based on gadolinium (Gd) complexes. The Gd3+ ion, with 
seven unpaired f-electrons, is a preferred substance for contrast enhancement in 
MRI due to its paramagnetic properties. Gd chelates are, however, not very selective International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and have low relaxivity compared to what is theoretically 
  possible.1 In addition, when using Gd chelates as contrast 
agents,   relatively high doses could be required due to the 
widespread distribution. Administration to patients with 
reduced renal clearance is linked to nephrogenic systemic 
fibrosis.2–4   Nephrogenic systemic fibrosis is a scleroma-
like fibrotic skin disorder observed for patients with renal 
impairment.   Deposits of collagen in tissues and skin are 
characteristic with skin thickening and hyperpigmentation as 
hallmarks. The disorder may have systemic involvement and 
in severe cases it can be fatal.5 Therefore it is of importance 
that low doses of Gd are used without losing contrast effect, 
which drives the research of finding more efficient Gd-based 
agents. For this reason, Gd oxide (Gd2O3) nanoparticles have 
gained attention.6–8 In contrast to superparamagnetic iron 
oxide particles, Gd2O3 can easily generate positive contrast, 
thereby avoiding loss of signal and image voids that generally 
occur when using susceptibility contrast agents. Such signal 
loss could make it difficult to detect the contrast agent and 
discriminate between the agent, tissue, and image artifacts.
In addition, the field of molecular imaging using MRI 
in conjunction with contrast agents is increasingly improv-
ing and different cell labeling contrast agents have been 
developed in recent years. For such cell labeling studies, the 
development of positive contrast agents like Gd2O3 nanopar-
ticles providing high signal per unit is of great interest.9 MRI 
combined with molecular imaging will allow monitoring of 
specific tissues or cell types, for instance detection of stem 
cell migration and cellular trafficking, differentiation, and 
transplant rejection. Other available methods for cell visu-
alization include genetic labels, radionuclides, or membrane 
dyes.10,11 However, MRI is among the least invasive of the 
currently available imaging methods. It is considered safe 
and would thus be preferred as a tracking method.
It is recognized that particulate agents of iron oxide, 
coated with dextran for example, can be internalized into a 
variety of cell types and labeling efficacy can be increased 
using different transfection agents, especially for cell types 
that are not naturally phagocytic.12–14 It has been shown ear-
lier that THP-1 monocytes labeled with Gd2O3 nanoparticles 
provide positive contrast in MRI.15 In the current work, the 
aim was to continue this research by visualizing intracellular 
particles with electron microscopy and to explore whether 
a hematopoietic progenitor cell line, Ba/F3, would take up 
the particles or not, and if a transfection agent could further 
improve uptake in the Ba/F3 cells. MRI was used to assess 
whether high MRI contrast could be obtained from the Gd2O3 
nanoparticle-labeled cells. This study is part of a long term 
goal to improve the possibilities to monitor, for instance, stem 
cell migration with MRI by taking advantage of the positive 
contrast rendered by Gd2O3 nanoparticles.
Materials and methods
gd2O3 nanoparticles
The polyol method16,17 was used for synthesis of the Gd2O3 
particles. GdCl3·6H2O (2 mmol) was dissolved in 10 mL 
diethylene glycol (DEG) by heating to 140°C. Solid sodium 
hydroxide (2.5 mmol) was dissolved in 10 mL DEG and sub-
sequently added to the Gd-containing solution. The tempera-
ture was raised to 180°C and held constant for 4 hours under 
reflux and magnetic stirring, yielding a colloid. The solubility 
product or stability constant for Gd2O3 (Ksp = [Gd3+]2[OH−]6) 
is of the order ∼10−31, as calculated from thermodynamic data, 
hence the oxide is unstable in water at neutral pH.15 However, 
the solubility kinetics is quite slow.
To exclude aggregates and ions, the particle solution 
was filtered and dialyzed. A Vivaspin® polyethersulfone 
filter (Sartorius Vivascience AG, Hanover, Germany) with 
pore size 0.2 µm was used and filtering was performed 
by centrifuging the solution (1750 rpm) until all fluid had 
passed the filter (about 30 minutes). Then the samples were 
dialyzed in Milli-Q water (Millipore Corporation, Billerica, 
MA) using a membrane with a pore size of 1000 molecular 
weight cut-off. Dialysis proceeded for 24 hours and the water 
was changed three times. The sample-to-volume ratio in the 
dialysis procedure was at least 1:1000.
Particles were characterized through high-resolution 
transmission electron microscopy using a Tecnai™ G2 
electron microscope (FEI Company, Hillsboro, OR) operated 
at 200 kV . X-ray photoelectron spectroscopy studies were 
performed using a Microlab 310F (Thermo VG Scientific, 
West Sussex, United Kingdom) with a hemispheric analyzer 
and unmonochromatized aluminum Kα photons (1486.6 eV). 
The pressure in the analysis chamber was approximately 
2 × 10−8 mbar and the resolution was determined from the 
full-width half-maximum of the gold (4f7/2) line, which was 
about 2 eV with pass energy 50 eV . Sample preparations for 
transmission electron microscopy and X-ray photoelectron 
spectroscopy are described in Klasson et al.15
cell culturing and labeling
A hematopoietic progenitor cell line, Ba/F3, was used in this 
study and compared to a monocytic cell line, THP-1. Ba/F3 is a 
murine pro B-cell line established from mouse fetal liver.18 The 
cell line grows in suspension (Roswell Park Memorial Institute 
1640 medium with 10% fetal bovine serum, 2 mM L-glutamine, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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25 mM HEPES, 50 µM 2-mercaptoethanol, 1% penicillin-strep-
tomycin and 5% interleukin-3 [Sigma-Aldrich, St Louis, MO] 
and is kept in a cell culture flask at 37°C in 5% carbon dioxide 
atmosphere. As for the THP-1 cells, they are human monocytic 
cells derived from a 1-year-old boy with acute monocytic leu-
kemia.19 They are phagocytic and grow in suspension (Roswell 
Park Memorial Institute 1640 medium with 10% fetal bovine 
serum, 2 mM L-glutamine, 1% penicillin-streptomycin) with 
the same atmospheric conditions as for Ba/F3.
Experiments were conducted as follows; cells were trans-
ferred to 24-well culturing plates and each sample contained 
one million cells in 1 mL of cell culture medium. Cells were 
exposed to Gd2O3 nanoparticles in two different   concentrations 
(0.5 mM and 2 mM). Prior to the   particle addition, half of 
the different cell samples were also treated with 10 µg/mL 
protamine sulfate (Sigma-Aldrich   Corporation, St Louis, MO) 
to investigate whether this could increase the particle uptake 
in especially the Ba/F3 cells. The samples were then incubated 
at 37°C in 5% carbon dioxide. THP-1 cells were incubated for 
2 hours, which in previous studies was sufficient for particle 
uptake.15 Pilot studies showed that doubling the incubation 
time to 4 hours did not significantly increase the uptake. 
Ba/F3 cells are not naturally phagocytic and therefore a longer 
incubation time of 24 hours was used for these cells.20 After 
incubation, the samples were transferred into Falcon tubes 
(BD Biosciences, Franklin Lakes, NJ) and washed twice with 
cell culture medium (centrifuged for 8 minutes at 1050 rpm). 
For T1 and T2 determination, cell pellets were resuspended in 
0.5 mL medium. Gelatin (0.5 mL, 2%) was added to each 
sample and then the samples were left to harden before MRI 
measurements.
Since both DEG and Gd can be toxic,21 viability of 
Gd2O3 incubated Ba/F3 cells were monitored to ensure that 
cells were viable prior to MRI measurements. For this, the 
cells were stained with trypan blue and counted in a Bürker 
chamber (Sigma-Aldrich, St Louis, MO) directly after 
24 hours, 48 hours, and 72 hours of incubation. THP-1 cells 
have previously been shown to tolerate treatment with these 
particles for an extended period of time.15
Electron microscopy was performed to visualize intracel-
lular Gd2O3 nanoparticles. Incubated cells were washed in cell 
culture medium and cell pellets were fixed in 2% glutaralde-
hyde with 0.1 M sodium cacodylate and 0.1 M sucrose, pH 7.2. 
After fixation, cells were rinsed in 0.15 M sodium cacodylate 
buffer and postfixed in 1% osmium tetroxide in 0.15 M sodium 
cacodylate buffer for 2 hours. After another rinse in sodium 
cacodylate buffer, the samples were dehydrated in 50% etha-
nol twice for 5 minutes and then contrasted with 2% uranyl 
acetate in 50% ethanol over night.   Continuing   dehydration 
steps was 70%, 85%, and 95% ethanol for 5 minutes each 
and 100% ethanol for 10 minutes.   Embedding was then per-
formed in 100% ethanol and Epon 812 (Shell Chemical LP, 
Houston, TX) for 30 minutes and then in pure Epon 812 for 
2 hours, then polymerized in 60°C for 48 hours. Ultrathin 
sections (60 nm) were cut with a diamond knife (DiATOME, 
Bienne, Switzerland) on a Reichert-Jung   Ultracut E (Leica 
  Microsystems, Wetzlar, Germany) and collected on copper 
grids. Sections were stained with uranyl acetate and lead 
citrate and examined in a JEM 1230 electron microscope 
(JEOL Ltd, Tokyo, Japan) at 100 kV . Photos were taken with 
a SC1000 ORIUS™ CCD camera using   DigitalMicrograph™ 
software (Gatan, Inc, Pleasanton, CA).
The cell samples were analyzed by inductively coupled 
plasma sector field mass spectrometry (ICP-SFMS; ALS 
Scandinavia AB, Luleå, Sweden) to quantify the concentra-
tion of Gd in each sample after incubation and washing. From 
these results uptake percentages were calculated.
MrI
The relaxation time measurements were performed with an 
Achieva 1.5T A-series (Philips, Amsterdam, Netherlands) 
MRI scanner using a head coil. The longitudinal T1 relaxation 
times were measured with inversion recovery sequences with 
turbo spin echo acquisition (turbo spin echo factor 9). Echo 
time was 29 milliseconds, repetition time was 10 seconds, 
and inversion recovery delay times were 125, 300, 500, 1000, 
2000, and 5000 milliseconds. The field of view was 200 mm 
and slice thickness 5 mm. The transverse T2 relaxation times 
were measured with a multiecho spin echo sequence with 
16 echoes at multiples of 20 milliseconds, repetition time 
was 1000 milliseconds. Field of view was 200 mm and slice 
thickness was 5 mm.
Relaxation time measurements were performed by plac-
ing Falcon test tubes containing the samples in a holder 
immersed in a bowl of water at 21°C ± 1°C. For data pre-
sented in the present work, two experimental sessions were 
performed. At each session, relaxation times in two cell types 
(Ba/F3 and THP-1) incubated with Gd2O3 nanoparticles with 
low (0.5 mM) and high (2 mM) Gd concentration respec-
tively treated and not treated with protamine sulfate were 
measured. This resulted in eight measurements per session. 
As a reference, five Gd-diethylene triamine pentacetic acid 
(Magnevist®; Bayer Schering Pharma AG, Berlin, Germany) 
samples all containing 0.1 mM Gd in water were spread 
out in different places in the tube holder to ensure that the 
measurements were stable throughout the coil.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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A monoexponential least-squares fit was performed on the 
data to retrieve T1 and T2. The fit was implemented in an in-
house developed Interactive Data Language   program (Exelis 
Visual Information Solutions, Boulder, CO).   Statistical 
analysis was obtained from GraphPad Prism® version 4 
(GraphPad Software, San Diego, CA).
Results
Particle characterization
Gd2O3 nanoparticle samples synthesized through the polyol 
method consist (as synthesized) of different sized particles as 
well as a large fraction of Gd ions. Dialysis was performed to 
remove the ion content and thereby an ion-free nanoparticle 
solution was obtained. The Gd content after 24 hours of 
dialysis decreased from an initial concentration of 100 mM 
to about 10 mM, consistent with previously published data 
regarding dialysis.9
To obtain information about the elemental composi-
tion of the particles, X-ray photoelectron spectroscopy 
measurements were performed. Results of dialyzed nano-
particle samples show a pure nanomaterial with reduced 
amount of hydrocarbon/DEG compared with nondialyzed 
material. For further details, see earlier published data.6,8,15 
Gd2O3-DEG particles have earlier been characterized by 
transmission electron microscopy showing crystalline 
particles with an average size of about 2–5 nm.9,16 In this 
work, crystalline particles in the same size range were 
obtained.
cell viability
The viability of Ba/F3 cells was approximately 77% before 
incubation with Gd2O3 nanoparticles. The corresponding 
value for THP-1 cells was approximately 90% before treat-
ment with particles. In a previous study,15 viability results 
for THP-1 cells were reported; this is therefore not further 
addressed in this work.
After 24 hours of incubation with Gd2O3 particles at 
2 mM Gd concentration, the viability of Ba/F3 cells had 
decreased slightly (Table 1), but not significantly. Samples 
were also investigated with or without protamine sulfate 
added, but there was no difference between these samples. 
After 48 hours and 72 hours of incubation the viability 
was principally retained. After 72 hours the viability of 
the sample incubated with Gd2O3 nanoparticles without 
protamine sulfate had decreased to 68%. However, this 
apparent decrease was within the standard deviation of the 
measurement error.
Visualization of intracellular particles
Electron microscopy images of Gd2O3 incubated cells show 
that THP-1 cells had a large cytoplasm and cellular parts 
near the cell surface indicating that they stretched out in 
phagocytic activity (Figure 1). In addition, particle contain-
ing vesicles were visible.
Ba/F3 cells consisted of a dominating nucleus. It is 
shown from the extracts in Figure 2 that Gd2O3 nanopar-
ticles resided in vacuoles inside the cells as well as outside 
the cell membrane in some cases. The overall results from 
electron microscopy images suggest that THP-1 cells con-
tain more particles in vacuoles than Ba/F3. It is shown that 
Ba/F3 bound particles to the cell surface (Figure 3) and 
in a few cases the cells had aggregated and particles were 
trapped in between the cells. The ability to attract particles 
near the cell membrane is, however, a prere  quisite for cell 
internalization. Visual examination of the different cell 
samples showed more particles in protamine sulfate-treated 
cells. This result was also supported by the Gd content 
analysis by inductively coupled plasma sector field mass 
spectrometry.
The analysis of Gd concentration showed a mean uptake 
percentage of 2% in Ba/F3 cells treated with protamine 
  sulfate. In nontreated Ba/F3 cells, the mean uptake percentage 
was 1% for the low concentration and 2% for the high 
concentration. THP-1 had higher uptake: 5% in protamine 
sulfate-treated cells and 3% and 4% in nontreated cells for 
the low and high incubation concentration, respectively. 
Figure 2B and D show representative parts of control cells 
containing no particles. In these samples there were not as 
many vacuoles/endosomes present indicating that the cells 
were not phagocytically activated.
Table 1 Ba/F3 cells incubated in 2 mM gadolinium compared to nontreated cells
2 mM gadolinium + protamine  
sulfate
2 mM gadolinium − 
protamine sulfate
Control + protamine  
sulfate
Control − protamine   
sulfate
24 hours of incubation 72% ± 5% 73% ± 7% 77% ± 5% 75% ± 6%
48 hours of incubation 70% ± 7% 72% ± 11% 81% ± 6% 70% ± 4%
72 hours of incubation 73% ± 3% 68% ± 5% 83% ± 7% 75% ± 7%
Notes: cells were also exposed or not exposed to transfection agent protamine sulfate. Figures in the table show percentages of viable cells.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(P = 0.08, pooled relaxivity across samples = 4.4 s−1 mM−1), 
whereas r2 of the treated THP-1 cells were different from the 
other samples (P = 0.005). The ratio r2/r1 was approximately 
three for all cell samples.
When observing signal intensity in the top panel of 
  Figure 5 (repetition time was 1000 milliseconds, echo 
time was 20 milliseconds), samples incubated with Gd2O3 
  nanoparticles in higher Gd concentration can be seen to appear 
brighter. This supports the notion that high signal intensity can 
be obtained with intracellular Gd2O3   nanoparticles. Samples 
incubated in 2 mM Gd with an uptake of 0.07  –0.11 mM were, 
with these parameters, comparable in intensity to 0.1 mM 
Gd-diethylene triamine pentacetic acid in water. In addition, 
the T1 image (Figure 5, bottom panel) shows approximately 
the same relaxation times for samples incubated in Gd2O3 
nanoparticles at 2 mM Gd and the Gd-  diethylene triamine pen-
tacetic acid samples, whereas   relaxation times of   nanoparticle 
samples incubated with 0.5 mM Gd were close to the values 
of cell control samples.
Discussion
Viability and solubility uptake
Results of the Ba/F3 viability study showed that the cells 
were viable after incubation with Gd2O3 nanoparticles and 
remained intact at the time for MRI measurement, which is 
essential for this work. Although the cells, especially Ba/F3, 
only partly took up the particles, they still were exposed 
to the Gd extracellularly, as the nanoparticles were not 
washed away during these observations. Taking this into 
account, the viability was not significantly reduced and this 
preserved good viability is confirmed by Faucher et al.22 It is 
very promising that Ba/F3 cells withstand the Gd and DEG 
exposure to the same extent as THP-1 (previously studied 
in Klasson et al.15 However, toxicology investigations of the 
Gd2O3 nanoparticles need more thorough viability studies 
and long term biological effects need to be evaluated. In 
addition, it has to be remembered that before considering 
Figure 1 representative image of THP-1 cell treated with 2.0 mM gadolinium shows 
several vacuoles containing gadolinium oxide nanoparticles and invaginations at the 
cell surface indicating phagocytic processes (left panel). Illustration of the phagocytic 
process: (1) nanoparticles in the extracellular fluid, (2) nanoparticles approaching the 
cell surface, (3) nanoparticles at the cell surface, and (4) nanoparticles internalized 
in cell vacuole (right panel).
Figure 2 representative electron microscopy images of cells: THP-1 in (A) and (B); 
Ba/F3 in (C) and (D). (A) and (C) show gadolinium oxide incubated cells (treated 
with protamine sulfate and 2.0 mM gadolinium). gadolinium oxide nanoparticles 
are visible inside vacuoles of the cell. Images (B) and (D) show control cells not 
treated at all. These cells do not have as many vacuoles indicating that they were 
not phagocytically active.
Figure 3 Ba/F3 cells with gadolinium oxide nanoparticles on cell surface. small 
endocytic invaginations (see inset) indicate a possible internalization process.
MrI
Samples incubated with Gd2O3 nanoparticles in higher Gd 
concentration contained higher amount of Gd and had higher 
relaxation rates (Figure 4). The trend was similar for both 
cell types. THP-1 cells treated with protamine sulfate and 
incubated in the higher Gd concentration had decreased 
relaxation rates at high Gd content (0.11 mM) compared 
to the expected value from the overall relaxivity trends 
(Table 2). In addition, relaxivity for protamine sulfate-
treated THP-1 cells seemed to be lower (r1 = 3.6 s−1 mM−1, 
r2 = 9.6 s−1 mM−1) compared to the relaxivity for the other 
samples (r1 $ 4.5 s−1 mM−1, r2 $ 13.4 s−1 mM−1). However, 
r1 from the different samples were not significantly different International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in vivo studies of the particles used as a regular contrast 
agent, other cappings have to be considered, hence gaining 
a stable, tolerable contrast agent.
As expected, Gd2O3 nanoparticles were shown to be intra-
cellularly located in THP-1 cells as well as in Ba/F3 cells. 
In the microscopy images, protamine   sulfate effect on 
both Ba/F3 and THP-1 cells was observed,   however not to 
any great extent. Higher particle content was observed in 
vacuoles in protamine sulfate-treated Ba/F3 compared to 
untreated Ba/F3 cells. THP-1 cells had high particle uptake 
in both protamine sulfate-treated as well as untreated cells. 
Because THP-1 is a naturally phagocytic cell type, this cell 
line is not dependent on a transfection agent for uptake. It 
should also be taken into account that THP-1 cells were only 
incubated for 2 hours, which is believed to be sufficient at 
regular   conditions. It could,   however, be beneficial to exceed 
that incubation time allowing the cells to interact with the 
transfection agent and particle solution for a longer period 
of time.
As previously mentioned, lower uptake was observed in 
endosomes and vacuoles in Ba/F3 cells than in THP-1 cells. 
In the electron microscopy images, extracellular Gd2O3 
  nanoparticles were noted near the cell membrane (Figure 3) 
and particles stuck in between cells. It is therefore probable 
that some of the measured Gd was not intracellular, but 
attached to the cell surface or located in between aggregated 
cell complexes. Another theory is that some of the intracellular 
particles could be located in the cytosol of the cells and there-
fore not clearly visible in the electron microscopy images.
In Ba/F3 cells, the low uptake was expected since these 
cells are not naturally phagocytic. However, lower uptake 
in THP-1 cells was observed in this work compared to a 
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Figure 4 relaxation of gadolinium oxide nanoparticles in THP-1 and Ba/F3 cells. samples were either treated with protamine sulfate or not and the cells were incubated with 
gadolinium oxide nanoparticles in two different gadolinium concentrations for each sample (0.5 mM or 2.0 mM).
Abbreviations: conc, concentration; gd, gadolinium.
Table 2 relaxivity values r1 and r2 (s−1 mM−1) at 1.5 T and 21°c 
for Ba/F3 and THP-1 cell samples incubated with gadolinium oxide 
nanoparticles with or without protamine sulfate treatment
r1 r2 r2/r1
Ba/F3 + protamine sulfate 5.3 ± 0.5 17.2 ± 1.3 3.2
Ba/F3 − protamine sulfate 4.5 ± 0.5 13.4 ± 1.0 3.0
THP-1 + protamine sulfate 3.6 ± 0.3   9.6 ± 0.9 2.7
THP-1 − protamine sulfate 4.7 ± 0.8 13.6 ± 1.0 2.9
Note: relaxivity calculations were based on gadolinium concentration in cells after 
treatment.
R
C
C
Ba/F3
High+ Low+ Low− High−
THP-1
2455
1199
Figure 5 Upper panel shows signal intensity of incubated cell samples (repetition 
time = 1000 milliseconds, echo time = 20 milliseconds). The first row is Ba/F3 
and the second row is THP-1. columns labeled “high” are treated with 2.0 mM 
gadolinium  and  “low”  with  0.5  mM  gadolinium.  columns  labeled  with  “+”  are 
protamine sulfate treated and with “−” are not treated with protamine sulfate. The 
rightmost samples (labeled c) are cell control samples with no particles. sample 
labeled r is gd-diethylene triamine pentacetic acid reference (0.1 mM gadolinium in 
water). Bottom panel shows corresponding T1 map, which shows different colors 
corresponding to different T1 times.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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previous study,15 which indicates that higher uptake, than 
seen in this work, is possible. According to the literature, the 
particle uptake in cells varies also at approximately similar 
experimental conditions.15,20,23,24 It is therefore concluded that 
different uptake might depend on the natural and biological 
difference in the cells in addition to different labeling meth-
ods and incubation times. To increase the internalization of 
particles, in particular Gd2O3 nanoparticles, other transfec-
tion agents, other incubation times, and higher incubation 
concentrations as well as surface modification of the particles 
can be considered. Dextran coating could for instance be an 
option, especially since dextran-coated superparamagnetic 
iron oxide particles show high cellular labeling efficacy.25 
In addition, these particles are larger than the Gd2O3 nano-
particles and the particle size can be the crucial parameter. 
Larger particles might interact easier with the cells and 
would be ingested faster. Also, the efficiency of membrane 
wrapping processes partly depends on particle size. Previous 
studies have observed that nanoparticles between 25–50 nm 
in diameters were internalized most efficiently.26 This implies 
that it could be beneficial to increase the size of the Gd2O3 
nanoparticles to make them more efficient for intracellular 
labeling. However, magnetic and relaxation properties might 
not be favored if particle size is increased.
MrI
There was no difference in r1 relaxivity between the differ-
ent cell samples treated with Gd2O3 nanoparticles, but for 
THP-1 cells, a lower r2 relaxivity was observed for protamine 
sulfate-treated cells. However, more samples might be 
needed to ensure these results. In addition, protamine sulfate-
treated cells might take up more particles concentrated to 
fewer   vacuoles/endosomes, whereas in protamine sulfate-
untreated cells the uptake might be spread in more and 
smaller   vacuoles, which could affect the relaxivity.
Gd2O3 nanoparticles in this work shortened the relaxation 
times with higher intracellular concentration. This is visual-
ized in Figure 5, where samples with higher concentration 
have higher signal intensity (top panel), and lower T1 values 
(bottom panel). In contrast, the sample with THP-1 cells that 
had internalized the highest Gd concentration (the rightmost 
sample in Figure 4) had a lower relaxation rate compared 
to what was expected from the general trend. This result is 
interpreted as emanating from aggregation and/or saturation 
in the cells. Aggregated particles lower the relaxation rate 
due to a decreased surface-to-bulk ratio. Since Gd in the 
particle cores does not directly contribute to the relaxation 
effect, a decreased surface-to-bulk ratio will lead to fewer 
Gd ions at the surface that could interact with intracellular 
protons. Decreased relaxation rate could also be an effect of 
vacuoles that are filled to saturation with particles. Saturated 
vacuoles act like macroparticles and the beneficial relaxation 
properties of nanoparticles are lost. However, according 
to Faucher et al,27 Gd2O3 aggregated nanoparticles could 
still act as an efficient “positive-T1” contrast agent at 1–3 T 
magnetic fields.
Conclusion
From the microscopy study of THP-1 and Ba/F3 cells 
incubated with Gd2O3 nanoparticles, vacuoles with vis-
ible particles were observed. Uptake in both Ba/F3 cells 
and THP-1 cells was increased by the transfection agent 
protamine sulfate. The MRI study showed that the relaxation 
times were shortened with increasing particle concentra-
tion and Gd2O3 nanoparticles are promising as a positive 
intracellular MRI contrast agent. For further studies on cell 
labeling, the   particles need to be improved regarding   capping 
stabilizing the particles from degradation as well as from 
  aggregation. In addition, cell internalization, especially in 
cells not normally phagocytic, needs to be enhanced by modi-
fying transfection methods and agents or optimizing incuba-
tion time. With these improvements it is possible to obtain 
an intracellular contrast agent generating positive contrast 
that could be used in pure stem cells and could contribute to 
the monitoring of stem cell migration.
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